Latest Articles and Analysis

The Centers for Disease Control and Prevention (CDC) released its National HIV Prevention and Care Objectives: 2026 Update on May 18, 2026, presenting the most recent national picture of the U.S. HIV...

New Phase 3 data show a single-tablet regimen of bictegravir/lenacapavir could finally bring one-pill simplicity to long-term HIV survivors locked into complex regimens by decades of drug resistance. The science is closing the treatment gap. Will our policy systems do the same?

CROI 2026 showcased breakthroughs alongside funding crisis disrupting global and domestic HIV services.

Long-acting injectable HIV treatments demonstrate clinical promise but face coverage and implementation barriers.

Q3 2024 Watch monitoring HCV treatment access across ADAPs, Medicaid, Veterans programs, and assistance initiatives.

ADAP coverage gaps for long-acting injectable HIV treatments and equity implications.

Major HIV research breakthroughs from CROI 2024: long-acting treatments and prevention advances.

European Commission approves lenacapavir, a novel six-month injectable for treatment-resistant HIV.

FDA extends Cabenuva to 2-month injections but insurance barriers continue to restrict patient access.

Merck-Gilead partnership on long-acting injectables Islatravir and Lenacapavir for HIV treatment.

FDA approves Cabenuva, first long-acting injectable HIV regimen offering monthly alternative to daily pills.